SCHEDULE Filed 2025-04-30 Event 2025-04-28 SEC 0001415889-25-011581 →

RA CAPITAL MANAGEMENT, L.P. → Jade Biosciences, Inc. JBIO

Stake: 4.10% Shares: 1,324,954 CUSIP: 008064206 Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

1 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

83 filings by this filer

82 other filings in the data moat

Short Interest · settle 2026-08-31

DTC 16.48

9,994,410 shares short · +3.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $8.62M

Point72 Asset Mgmt

Post-Filing Returns · since 2025-04-28 on JBIO

+1 day

0.0%

+5 days

0.0%

+30 days

0.0%

+60 days

0.0%

+90 days

0.0%

+180 days

0.0%

Anchor price 22.45 on closest trading day on/after 2025-04-28. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-25	Eisner Mark	director	Award	47,675	$21.81	$1.04M

Other 13D/G Filings on Jade Biosciences, Inc.

Filed	Form	Filer	Stake	Shares
2026-06-09	SCHEDULE 13D/A	Fairmount Funds Management LLC	19.99%	14,069,494	view →
2025-04-30	SCHEDULE	Atlas Venture Fund XII, L.P.	20.00%	51,406	view →
2024-06-20	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →
2024-02-20	SC	Sofinnova Venture Partners X, L.P.	—	—	view →
2022-07-20	SC	Atlas Venture Fund XII, L.P.	—	—	view →

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2026-09-03	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-07	SCHEDULE 13D/A	Climb Bio, Inc. CLYM	33.00%	23,249,186	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →
2026-06-15	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC. ARTV	36.60%	17,811,623	view →
2026-06-15	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	5,138,703	view →
2026-06-03	SCHEDULE 13G	Editas Medicine, Inc. EDIT	—	—	view →
2026-05-21	SCHEDULE 13G	Sana Biotechnology, Inc. SANA	—	—	view →
2026-05-14	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	6,116,140	view →

Showing 20 of 82

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →